Oxford Biomedica (otc) ( (OXBDF) ) has released its Q2 earnings. Here is a breakdown of the information Oxford Biomedica (otc) presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Oxford Biomedica, a leading cell and gene therapy contract development and manufacturing organization (CDMO), specializes in viral vector manufacturing and collaborates with pharmaceutical and biotechnology companies worldwide.
In its interim results for the first half of 2025, Oxford Biomedica reported a 44% increase in total revenues, reaching £73.2 million, driven by strong demand for its CDMO services. The company also re-entered the FTSE 250 index, reflecting its growing market presence.
Key financial highlights include a significant improvement in profitability, with an operating EBITDA loss reduced to £8.3 million from £20.3 million the previous year. The company secured £149 million in contracted client orders, a 166% year-on-year increase, and strengthened its balance sheet with a new loan facility and equity placing.
Looking ahead, Oxford Biomedica remains confident in its growth trajectory, with revenue guidance for 2025 set at £160-170 million and expectations for continued revenue growth in the coming years. The company plans strategic investments to expand its global CDMO network, particularly in the US, to meet increasing client demand.
With a strong market position and a diversified client portfolio, Oxford Biomedica is well-positioned for sustainable growth, aiming to deliver life-changing therapies to patients worldwide.